CJC-1295 (no DAC) vs GHRH (1–44)
Both CJC-1295 (no DAC) and GHRH (1–44) are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | GHRH (1–44) |
|---|---|---|
| Evidence Grade | B | A |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 1 mcg/kg IV (diagnostic test) |
| Clinics Indexed | 156 | 22 |
| Categories | growth-hormone, anti-aging, recovery | growth-hormone |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.